Michael Fridrik

3.9k total citations · 1 hit paper
83 papers, 1.8k citations indexed

About

Michael Fridrik is a scholar working on Oncology, Pathology and Forensic Medicine and Hematology. According to data from OpenAlex, Michael Fridrik has authored 83 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 38 papers in Oncology, 30 papers in Pathology and Forensic Medicine and 25 papers in Hematology. Recurrent topics in Michael Fridrik's work include Lymphoma Diagnosis and Treatment (21 papers), Chronic Lymphocytic Leukemia Research (16 papers) and Breast Cancer Treatment Studies (16 papers). Michael Fridrik is often cited by papers focused on Lymphoma Diagnosis and Treatment (21 papers), Chronic Lymphocytic Leukemia Research (16 papers) and Breast Cancer Treatment Studies (16 papers). Michael Fridrik collaborates with scholars based in Austria, Germany and United States. Michael Fridrik's co-authors include JR Redman, Peter McLaughlin, F Swan, Sundar Jagannath, Fernando Cabanillas, P. Salvador, FB Hagemeister, Richard Greil, H. Hausmaninger and Michael Gnant and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Michael Fridrik

78 papers receiving 1.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP)

1988 487 citations Michael Fridrik et al. Blood profile →

Peers

Countries citing papers authored by Michael Fridrik

Since Specialization

Citations

This map shows the geographic impact of Michael Fridrik's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Fridrik with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Fridrik more than expected).

Fields of papers citing papers by Michael Fridrik

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Fridrik. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Fridrik. The network helps show where Michael Fridrik may publish in the future.

Co-authorship network of co-authors of Michael Fridrik

This figure shows the co-authorship network connecting the top 25 collaborators of Michael Fridrik. A scholar is included among the top collaborators of Michael Fridrik based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael Fridrik. Michael Fridrik is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Torsade de pointes in a patient with severe hypercalcaemia and multiple myeloma. 2017 ·PubMed ·David Fuchs, Daniela Voskova, (unknown), (unknown), Michael Fridrik	1
2	Health-Related Quality of Life in Patients with Relapsed/Refractory Multiple Myeloma during Treatment with Ixazomib-Thalidomide-Dexamethasone Followed By Ixazomib Maintenance 2017 ·Blood ·Heinz Ludwig, Wolfram Pönisch, Alexander Egle, Stefan Knop, Martin Schreder, Daniel Lechner, Roman Hájek, Eberhard Gunsilius, Michael Fridrik, Andreas Petzer, Katja Weisel, Dietger Niederwieser, Axel Hinke, Richard Greil, Niklas Zojer	1
3	A prospective, multicenter pilot study to investigate the feasibility and safety of a 1-year controlled exercise training after adjuvant chemotherapy in colorectal cancer patients 2017 ·Supportive Care in Cancer ·(unknown), (unknown), Michael Fridrik, (unknown), Andreas Leiherer, August Zabernigg, Richard Greil, Wolfgang Eisterer, Jörg Tschmelitsch, Alois Lang, Sophie Frantal, Sonja Burgstaller, Michael Gnant, Josef Thaler	8
4	Oxaliplatin/Irinotecan/Bevacizumab Followed by Docetaxel/ Bevacizumab in Inoperable Locally Advanced or Metastatic Gastric Cancer Patients – AGMT_GASTRIC-3 2017 ·Anticancer Research ·Ewald Wöll, Josef Thaler, Felix Keil, Birgit Gruenberger, Michael Hejna, Wolfgang Eisterer, Michael Fridrik, Hanno Ulmer, (unknown), Florian Huemer, Lukas Weiß, Richard Greil	9
5	Experience with lenalidomide in an Austrian non-study population with advanced myelofibrosis 2013 ·Wiener klinische Wochenschrift ·Sonja Burgstaller, Michael Fridrik, (unknown), Thomas Kühr, Heinz Ludwig, (unknown), (unknown), (unknown), Ernst Schlögl, (unknown), Josef Thaler, Heinz Gisslinger	4
6	A case of acute myeloid leukemia (AML) with an unreported combination of chromosomal abnormalities: gain of isochromosome 5p, tetrasomy 8 and unbalanced translocation der(19)t(17;19)(q23;p13) 2013 ·Molecular Cytogenetics ·Christian Paar, (unknown), Daniela Voskova, Michael Fridrik, Herbert Stekel, Jörg Berg	1
7	Sentinel Node Biopsy After Primary Chemotherapy in Breast Cancer: A Note of Caution from Results of ABCSG-14 2011 ·The Breast Journal ·Christoph Tausch, Günther Steger, A. Haid, R. Jakesz, Michael Fridrik, Roland Reitsamer, Sabine Pöstlberger, Alois Lang, Michael Gnant, Richard Greil	5
8	Multicenter Phase II Study of Pegylated Liposomal Doxorubicin in Combination with Vinorelbine as First-Line Treatment in Elderly Patients with Metastatic Breast Cancer 2009 ·Oncology Research and Treatment ·Brigitte Mlineritsch, (unknown), Johannes Andel, Michael Fridrik, Martin Moik, (unknown), Gudrun Russ, (unknown), Richard Greil	12
9	Sentinel node mapping performed before preoperative chemotherapy may avoid axillary dissection in breast cancer patients with negative or micrometastatic sentinel nodes 2008 ·The American Journal of Surgery ·Peter Schrenk, Christoph Tausch, (unknown), (unknown), Michael Fridrik, W. Wayand	24
10	Three-dimensional ultrasound to assess the response to treatment in gynecological malignancies 2005 ·Gynecologic Oncology ·Cemil Yaman, Michael Fridrik	15
11	Long-term results of dose density therapy in patients with aggressive lymphoma 2004 ·Annals of Hematology ·Michael Fridrik, H. Hausmaninger, Werner Linkesch, Richard Greil, Otto Krieger, (unknown), (unknown), (unknown), (unknown)	3
12	Sentinel Node Biopsy Performed Before Preoperative Chemotherapy for Axillary Lymph Node Staging in Breast Cancer 2003 ·The Breast Journal ·Peter Schrenk, (unknown), Michael Fridrik, W. Wayand	52
13	Randomized Trial of Low-Dose Chemotherapy Added to Tamoxifen in Patients With Receptor-Positive and Lymph Node–Positive Breast Cancer 1999 ·Journal of Clinical Oncology ·R. Jakesz, H. Hausmaninger, K. Haider, E. Kubista, H. Samonigg, Michael Gnant, D. Manfreda, G. Tschurtschenthaler, R. Kolb, M. Stierer, Michael Fridrik, Brigitte Mlineritsch, P. Steindorfer, Martina Mittlböck, Guenther G. Steger	28
14	First-line treatment of Waldenström's disease with cladribine 1997 ·Annals of Hematology ·Michael Fridrik, Gerald Jäger, (unknown), O. Krieger, Andreas Chott, Peter Bettelheim	44
15	CEOP-IMVP-Dexa in the treatment of aggressive lymphomas: an Austrian multicenter trial. 1996 ·Journal of Clinical Oncology ·Michael Fridrik, H. Hausmaninger, Werner Linkesch, (unknown), Heinz Sill, M. Neubauer, H. L. Seewann, (unknown), Renate Haidinger, (unknown), (unknown), (unknown), Markus Falk, T Radaszkiewicz	9
16	5-Fluorouracil and Folinic Acid with or without Alpha-2c Interferon in the Treatment of Metastatic Colorectal Cancer: Preliminary Results of a Multicenter Prospective Randomized Phase-Ill Trial 1995 ·Oncology Research and Treatment ·(unknown), H. Hausmaninger, Heinz Ludwig, Michael Fridrik, Henrik Schmidt, Brigitte Mlineritsch, Martin Pecherstorfer, G. Michlmayr, (unknown), H. Samonigg	1
17	Randomised phase II study of epirubicin-vindesine versus mitoxantrone-vindesine in metastatic breast cancer 1995 ·European Journal of Cancer ·H. Hausmaninger, M. Lehnert, Guenther G. Steger, P. Sevelda, G. Tschurtschenthaler, (unknown), Michael Fridrik, H. Samonigg, (unknown), D. Manfreda, Renate Haidinger, (unknown), Georg Kemmler	9
18	Toxicity and preliminary results with a new eight‐drug regimen (CEOP‐IMVP‐DEXA) in the treatment of aggressive lymphomas 1991 ·Hematological Oncology ·Michael Fridrik, H. Hausmaninger, G. Michlmayr, Renate Haidinger, H. L. Seewann, Martin Lehnert	1
19	Vindesine-Epirubicin versus Vindesine-Mitoxantrone in Metastatic Breast Cancer 1989 ·Oncology Research and Treatment ·H. Hausmaninger, M. Lehnert, G.G. Steger, P. Sevelda, G. Michlmayr, (unknown), Michael Fridrik, (unknown), (unknown), D. Manfreda, Renate Haidinger, (unknown), A Neiss	8
20	Morphological and immunological changes of hairy cell leukemia during ?-2-interferon therapy 1989 ·Annals of Hematology ·Michael Fridrik, (unknown), (unknown), (unknown), G�nther Gastl, Christoph Huber, (unknown), (unknown)	3

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact